粘膜免疫
免疫学
2019年冠状病毒病(COVID-19)
生物
冠状病毒
免疫
疾病
病毒学
传染病(医学专业)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
医学
免疫系统
病理
作者
Bingjie Ma,Mengxiao Tao,Zhili Li,Quanfang Zheng,Wu Haigang,Chen Pei-rong
出处
期刊:Virology
[Elsevier]
日期:2024-05-01
卷期号:593: 110026-110026
被引量:1
标识
DOI:10.1016/j.virol.2024.110026
摘要
Virus-associated infectious diseases are highly detrimental to human health and animal husbandry. Among all countermeasures against infectious diseases, prophylactic vaccines, which developed through traditional or novel approaches, offer potential benefits. More recently, mucosal vaccines attract attention for their extraordinary characteristics compared to conventional parenteral vaccines, particularly for mucosal-related pathogens. Representatively, coronavirus disease 2019 (COVID-19), a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), further accelerated the research and development efforts for mucosal vaccines by thoroughly investigating existing strategies or involving novel techniques. While several vaccine candidates achieved positive progresses, thus far, part of the current COVID-19 mucosal vaccines have shown poor performance, which underline the need for next-generation mucosal vaccines and corresponding platforms. In this review, we summarized the typical mucosal vaccines approved for humans or animals and sought to elucidate the underlying mechanisms of these successful cases. In addition, mucosal vaccines against COVID-19 that are in human clinical trials were reviewed in detail since this public health event mobilized all advanced technologies for possible solutions. Finally, the gaps in developing mucosal vaccines, potential solutions and prospects were discussed. Overall, rational application of mucosal vaccines would facilitate the establishing of mucosal immunity and block the transmission of viral diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI